Wednesday, January 28, 2026 1/28/2026

The Convergence of Titin and Elongator in Amyotrophic Lateral Sclerosis

Award Number: R15NS090384
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2015
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

The Convergence of Titin and Elongator in Amyotrophic Lateral Sclerosis - Project Summary Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease that ravages motor neurons and the voluntary muscles they innervate, is the most common motor neuron disease. Nucleolar stress was recently identified as an underlying pathogenic mechanism in ALS, common to both familial and sporadic forms, that triggers the degeneration of motor neurons. This proposal describes the discovery that titin, the largest protein in the human proteome, is present in the nucleolus of motor neurons and seeks to demonstrate that its function in this organelle and its regulation by the Elongator complex converge on the nucleolus as a nexus of disease pathogenesis in ALS. The proposal includes three Aims. In the first aim, titin’s presence in neurons will be fully characterized including identification of the specific central and peripheral nervous system cell types that exhibit nucleolar. The second aim will test the hypothesis that titin, encoded by TTN, is required for motor neuron homeostasis and that titin dysfunction represents a novel underlying pathogenic mechanism in ALS. The use of a conditional knockout mouse where TTN is selectively ablated in motor neurons will serve as a powerful approach for investigating this hypothesis. The third aim seeks to understand why mutations in the Elongator complex are associated with ALS and posits that Elongator may actually regulate the production of titin as a common underlying mechanism of disease. Mice in which the Elongator protein 1 (Elp1) is selectively ablated in motor neurons exhibit severely compromised motor function, demonstrating that the loss of Elp1 is sufficient to arrive at an ALS phenotype. These mice again provide a powerful tool for investigating Elongator targets whose misregulation contribute to ALS. Accomplishment of the described specific aims will significantly advance our understanding of the underlying molecular and cellular pathways that go awry to precipitate the onset and progression of ALS and will identify new targets for the development of effective therapeutics to treat the disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $385,521 )
2022	2022	MONTANA STATE UNIVERSITY-BILLINGS	1500 UNIVERSITY DR	BILLINGS	MT	59101	YELLOWSTONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	9/26/2022	COMPETING CONTINUATION	$385,521
2022	2018	MONTANA STATE UNIVERSITY-BILLINGS	1500 UNIVERSITY DR	BILLINGS	MT	59101	YELLOWSTONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	11/27/2021	COMPETING CONTINUATION	$0
														Subtotal = $385,521

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2015	MONTANA STATE UNIVERSITY-BILLINGS	1500 UNIVERSITY DR	BILLINGS	MT	59101	YELLOWSTONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/13/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $395,533 )
2018	2018	MONTANA STATE UNIVERSITY-BILLINGS	1500 UNIVERSITY DR	BILLINGS	MT	59101	YELLOWSTONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	7/10/2018	COMPETING CONTINUATION	-$31,327
2018	2018	MONTANA STATE UNIVERSITY-BILLINGS	1500 UNIVERSITY DR	BILLINGS	MT	59101	YELLOWSTONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	6/8/2018	COMPETING CONTINUATION	$426,860
														Subtotal = $395,533

Issue Date FY: 2015 ( Subtotal = $333,007 )
2015	2015	MONTANA STATE UNIVERSITY-BILLINGS	1500 N. 30TH STREET	BILLINGS	MT	59101	YELLOWSTONE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	8/10/2015	NEW	$333,007
														Subtotal = $333,007

Grand Total All Awards = $1,114,061

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Convergence of Titin and Elongator in Amyotrophic Lateral Sclerosis

Award Number: R15NS090384

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2015

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer